世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Point of Care Diagnostics市場:製品別(グルコースモニタリングキット、感染症検査キット、妊娠・不妊検査キット、血液検査キット、循環代謝モニタリングキット、尿検査キット、コレステロール検査ストリップ、薬物乱用検査キット、その他)、処方形態別(処方ベースデバイス、OTCベースデバイス)、エンドユーザー別(専門診断センター、研究ラボ、ホームケア、その他)。世界の市場機会分析および産業予測、2020-2030年


Point of Care Diagnostics Market By Product (Glucose Monitoring Kits, Infectious Diseases Testing Kits, Pregnancy And Fertility Testing Kits, Hematology Testing Kits, Cardiometabolic Monitoring Kits, Urinalysis Testing Kits, Cholesterol Test Strips, Drugs Abuse Testing Kits, Others), By Mode Of Prescription (Prescription Based Devices, Otc Based Devices), By End User (Professional Diagnostic Centers, Research Laboratories, Home Care, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

ポイントオブケア(POC)検査とは、検査室以外で行われる診断方法のことである。POC検査は、コレステロール値やグルコース値の検査、酵素分析、薬物乱用検査、感染症診断、妊娠検査など、様々なPOC診断機器によっ... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Allied Market Research
アライドマーケットリサーチ
2022年5月31日 US$5,939
シングルユーザーライセンス
ライセンス・価格情報・注文方法はこちら
215 英語

 

サマリー

ポイントオブケア(POC)検査とは、検査室以外で行われる診断方法のことである。POC検査は、コレステロール値やグルコース値の検査、酵素分析、薬物乱用検査、感染症診断、妊娠検査など、様々なPOC診断機器によって行われる。また、心臓マーカー、便潜血検査、血液ガス検査などもPOC診断機器を用いて実施することが可能です。
様々な感染症の増加や、政府・非政府団体による健康意識向上のための様々な取り組みが、世界のポイントオブケア診断市場を牽引する主な要因となっています。また、POC診断機器の技術的進歩や在宅POC機器の導入、医療費の増加も市場の成長を後押ししています。しかし、POC診断機器の承認に関する政府の厳しい規制やPOC機器に対する償還の問題は、市場の成長を阻害する主な阻害要因の一つです。さらに、中国やインドなどの発展途上国は、POC診断の世界市場に大きな成長機会を提供しています。
ポイントオブケア診断の世界市場は、製品、エンドユーザー、処方形態、地域に基づいて区分されています。
製品別では、POC診断キット市場は、グルコースモニタリングキット、感染症検査キット、妊娠・不妊検査キット、血液検査キット、循環代謝モニタリングキット、尿検査キット、コレステロール検査ストリップ、乱用薬物検査キット、その他に区分される。このうち、グルコースモニタリングキットは、世界的な糖尿病罹患率の上昇に伴い、POC診断薬市場の主流となっています。しかし、予測期間中は感染症検査キットが最も急速に成長している分野です。これは、さまざまな感染症に対する意識の高まり、製品の急速な発売、政府機関が実施する公共の場での無料検診の取り組みによるものです。
エンドユーザー別では、専門的な診断センター、研究所、家庭、その他に分類され、これらのエンドユーザーの中では、専門的な診断センターが世界のポイントオブケア診断市場を支配しています。
ポイントオブケア診断薬の世界市場は、処方箋に基づくポイントオブケア診断薬とOTCに基づくポイントオブケア診断薬に分類されます。処方箋ベースのポイントオブケア診断薬は、医療施設での使用頻度が最も高く、医療従事者によって処方されます。
地域的には、北米、欧州、アジア太平洋、LAMEAの4つの主要地域で区分されます。ポイントオブケア診断薬市場では、北米が最大の市場シェアを占めています。アジア太平洋地域は、新興国における主要企業の注力度の高まりと、同地域の医療インフラの改善により、最大の成長が期待できる地域として浮上すると予想されます。
本レポートでは、Abbott Laboratories、Siemens AG、Hoffmann-La Roche Ltd、SINOCARE INC.、Johnson & Johnson、Sysmex Corporation、NOVA Biomedical、Danaher Corporation、Becton Dickinson, and Company、Bio-Rad laboratoriesなどのPOC市場で活動する主要企業の競合分析およびプロファイルを広範に提供しています。
ステークホルダーにとっての主なメリット

本レポートは、世界のポイントオブケア診断キット市場規模を現在の動向と将来予測とともに詳細に分析し、差し迫った投資ポケットを解明します。
2021年から2030年までの市場分析を提供しており、利害関係者が市場の優勢な機会を活用することを可能にすると期待されます。
地域の包括的な分析は、地域市場を理解し、戦略的な事業計画を促進し、優勢な機会を決定するのに役立ちます。
主要企業のプロファイルと成長戦略は、世界のPoint of Care Diagnostic Kit市場の競争展望を理解するために徹底的に分析されています。

ページTOPに戻る


目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Glucose Monitoring Kits
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Infectious Diseases Testing Kits
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Pregnancy And Fertility Testing Kits
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Hematology Testing Kits
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Cardiometabolic Monitoring Kits
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Urinalysis Testing Kits
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Cholesterol Test Strips
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
4.9 Drugs Abuse Testing Kits
4.9.1 Key market trends, growth factors and opportunities
4.9.2 Market size and forecast, by region
4.9.3 Market analysis by country
5.0 Others
5.0.1 Key market trends, growth factors and opportunities
5.0.2 Market size and forecast, by region
5.0.3 Market analysis by country
CHAPTER 5: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION
5.1 Overview
5.1.1 Market size and forecast
5.2 Prescription Based Devices
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Otc Based Devices
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: POINT OF CARE DIAGNOSTICS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Professional Diagnostic Centers
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Research Laboratories
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Home Care
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Others
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: POINT OF CARE DIAGNOSTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product
7.2.3 North America Market size and forecast, by Mode Of Prescription
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Product
7.2.5.1.2 Market size and forecast, by Mode Of Prescription
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Product
7.2.5.2.2 Market size and forecast, by Mode Of Prescription
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Product
7.2.5.3.2 Market size and forecast, by Mode Of Prescription
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product
7.3.3 Europe Market size and forecast, by Mode Of Prescription
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Product
7.3.5.1.2 Market size and forecast, by Mode Of Prescription
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Product
7.3.5.2.2 Market size and forecast, by Mode Of Prescription
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Product
7.3.5.3.2 Market size and forecast, by Mode Of Prescription
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Product
7.3.5.4.2 Market size and forecast, by Mode Of Prescription
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Product
7.3.5.5.2 Market size and forecast, by Mode Of Prescription
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Product
7.3.5.6.2 Market size and forecast, by Mode Of Prescription
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product
7.4.3 Asia-Pacific Market size and forecast, by Mode Of Prescription
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Product
7.4.5.1.2 Market size and forecast, by Mode Of Prescription
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Product
7.4.5.2.2 Market size and forecast, by Mode Of Prescription
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Product
7.4.5.3.2 Market size and forecast, by Mode Of Prescription
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Product
7.4.5.4.2 Market size and forecast, by Mode Of Prescription
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Product
7.4.5.5.2 Market size and forecast, by Mode Of Prescription
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest Of Asia Pacific
7.4.5.6.1 Market size and forecast, by Product
7.4.5.6.2 Market size and forecast, by Mode Of Prescription
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product
7.5.3 LAMEA Market size and forecast, by Mode Of Prescription
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Product
7.5.5.1.2 Market size and forecast, by Mode Of Prescription
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Product
7.5.5.2.2 Market size and forecast, by Mode Of Prescription
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Product
7.5.5.3.2 Market size and forecast, by Mode Of Prescription
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Product
7.5.5.4.2 Market size and forecast, by Mode Of Prescription
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Johnson and Johnson
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 sysmex corporation
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Nova Biomedical
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Danaher Corporation
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Becton Dickinson and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 bioMrieux SA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Abbott Laboratories
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Siemens AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Hoffmann La Roche Ltd
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sinocare Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR GLUCOSE MONITORING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 3. POINT OF CARE DIAGNOSTICS MARKET GLUCOSE MONITORING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR INFECTIOUS DISEASES TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 5. POINT OF CARE DIAGNOSTICS MARKET INFECTIOUS DISEASES TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR PREGNANCY AND FERTILITY TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 7. POINT OF CARE DIAGNOSTICS MARKET PREGNANCY AND FERTILITY TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR HEMATOLOGY TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 9. POINT OF CARE DIAGNOSTICS MARKET HEMATOLOGY TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR CARDIOMETABOLIC MONITORING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 11. POINT OF CARE DIAGNOSTICS MARKET CARDIOMETABOLIC MONITORING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR URINALYSIS TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 13. POINT OF CARE DIAGNOSTICS MARKET URINALYSIS TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 14. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR CHOLESTEROL TEST STRIPS, BY REGION , 2020-2030,($MILLION)
TABLE 15. POINT OF CARE DIAGNOSTICS MARKET CHOLESTEROL TEST STRIPS BY COUNTRY, 2020-2030,($MILLION)
TABLE 16. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR DRUGS ABUSE TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 17. POINT OF CARE DIAGNOSTICS MARKET DRUGS ABUSE TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 19. POINT OF CARE DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 21. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR PRESCRIPTION BASED DEVICES, BY REGION , 2020-2030,($MILLION)
TABLE 22. POINT OF CARE DIAGNOSTICS MARKET PRESCRIPTION BASED DEVICES BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR OTC BASED DEVICES, BY REGION , 2020-2030,($MILLION)
TABLE 24. POINT OF CARE DIAGNOSTICS MARKET OTC BASED DEVICES BY COUNTRY, 2020-2030,($MILLION)
TABLE 25. GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 26. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR PROFESSIONAL DIAGNOSTIC CENTERS, BY REGION , 2020-2030,($MILLION)
TABLE 27. POINT OF CARE DIAGNOSTICS MARKET PROFESSIONAL DIAGNOSTIC CENTERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 28. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR RESEARCH LABORATORIES, BY REGION , 2020-2030,($MILLION)
TABLE 29. POINT OF CARE DIAGNOSTICS MARKET RESEARCH LABORATORIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 30. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR HOME CARE, BY REGION , 2020-2030,($MILLION)
TABLE 31. POINT OF CARE DIAGNOSTICS MARKET HOME CARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 32. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 33. POINT OF CARE DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 34. POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 35. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 36. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 37. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 38. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 39. U.S. POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 40. U.S. POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 41. U.S. POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 42. CANADA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 43. CANADA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 44. CANADA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 45. MEXICO POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 46. MEXICO POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 47. MEXICO POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 48. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 49. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 50. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 51. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 52. GERMANY POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 53. GERMANY POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 54. GERMANY POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 55. FRANCE POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 56. FRANCE POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 57. FRANCE POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 58. U.K. POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 59. U.K. POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 60. U.K. POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 61. ITALY POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 62. ITALY POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 63. ITALY POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. SPAIN POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. SPAIN POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 66. SPAIN POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 67. REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 68. REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 69. REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 70. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 71. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 72. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 73. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 74. JAPAN POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 75. JAPAN POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 76. JAPAN POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 77. CHINA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 78. CHINA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 79. CHINA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 80. AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 81. AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 82. AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 83. INDIA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 84. INDIA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 85. INDIA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 86. SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 87. SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 88. SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 89. REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 91. REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 92. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 93. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 94. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 95. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 96. BRAZIL POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 97. BRAZIL POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 98. BRAZIL POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 99. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 100. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 101. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 102. SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 103. SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 104. SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 105. REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 106. REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 107. REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 108.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 109.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 110.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 111.JOHNSON AND JOHNSON: NET SALES,
TABLE 112.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 113.SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 114.SYSMEX CORPORATION: OPERATING SEGMENTS
TABLE 115.SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 116.SYSMEX CORPORATION: NET SALES,
TABLE 117.SYSMEX CORPORATION: KEY STRATERGIES
TABLE 118.NOVA BIOMEDICAL: COMPANY SNAPSHOT
TABLE 119.NOVA BIOMEDICAL: OPERATING SEGMENTS
TABLE 120.NOVA BIOMEDICAL: PRODUCT PORTFOLIO
TABLE 121.NOVA BIOMEDICAL: NET SALES,
TABLE 122.NOVA BIOMEDICAL: KEY STRATERGIES
TABLE 123.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 124.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 125.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 126.DANAHER CORPORATION: NET SALES,
TABLE 127.DANAHER CORPORATION: KEY STRATERGIES
TABLE 128.BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 129.BECTON DICKINSON AND COMPANY: OPERATING SEGMENTS
TABLE 130.BECTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 131.BECTON DICKINSON AND COMPANY: NET SALES,
TABLE 132.BECTON DICKINSON AND COMPANY: KEY STRATERGIES
TABLE 133.BIOMRIEUX SA: COMPANY SNAPSHOT
TABLE 134.BIOMRIEUX SA: OPERATING SEGMENTS
TABLE 135.BIOMRIEUX SA: PRODUCT PORTFOLIO
TABLE 136.BIOMRIEUX SA: NET SALES,
TABLE 137.BIOMRIEUX SA: KEY STRATERGIES
TABLE 138.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 139.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 140.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 141.ABBOTT LABORATORIES: NET SALES,
TABLE 142.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 143.SIEMENS AG: COMPANY SNAPSHOT
TABLE 144.SIEMENS AG: OPERATING SEGMENTS
TABLE 145.SIEMENS AG: PRODUCT PORTFOLIO
TABLE 146.SIEMENS AG: NET SALES,
TABLE 147.SIEMENS AG: KEY STRATERGIES
TABLE 148.HOFFMANN LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 149.HOFFMANN LA ROCHE LTD: OPERATING SEGMENTS
TABLE 150.HOFFMANN LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 151.HOFFMANN LA ROCHE LTD: NET SALES,
TABLE 152.HOFFMANN LA ROCHE LTD: KEY STRATERGIES
TABLE 153.SINOCARE INC.: COMPANY SNAPSHOT
TABLE 154.SINOCARE INC.: OPERATING SEGMENTS
TABLE 155.SINOCARE INC.: PRODUCT PORTFOLIO
TABLE 156.SINOCARE INC.: NET SALES,
TABLE 157.SINOCARE INC.: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2.POINT OF CARE DIAGNOSTICS MARKET,2020-2030
FIGURE 3.POINT OF CARE DIAGNOSTICS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.POINT OF CARE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.POINT OF CARE DIAGNOSTICS MARKET,BY PRODUCT,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF GLUCOSE MONITORING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASES TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PREGNANCY AND FERTILITY TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CARDIOMETABOLIC MONITORING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF URINALYSIS TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CHOLESTEROL TEST STRIPS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF DRUGS ABUSE TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 21.POINT OF CARE DIAGNOSTICS MARKET,BY MODE OF PRESCRIPTION,2020(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PRESCRIPTION BASED DEVICES POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTC BASED DEVICES POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 24.POINT OF CARE DIAGNOSTICS MARKET,BY END USER,2020(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PROFESSIONAL DIAGNOSTIC CENTERS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF RESEARCH LABORATORIES POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF HOME CARE POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 29.POINT OF CARE DIAGNOSTICS MARKET BY REGION,2020
FIGURE 30.U.S. POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 31.CANADA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 32.MEXICO POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 33.GERMANY POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 34.FRANCE POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 35.U.K. POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 36.ITALY POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 37.SPAIN POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 38.REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 39.JAPAN POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 40.CHINA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 41.AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 42.INDIA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 43.SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 44.REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 45.BRAZIL POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 46.SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 47.SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 48.REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 52.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53.COMPETITIVE DASHBOARD
FIGURE 54.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 55.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
FIGURE 56.SYSMEX CORPORATION.: NET SALES ,($MILLION)
FIGURE 57.NOVA BIOMEDICAL.: NET SALES ,($MILLION)
FIGURE 58.DANAHER CORPORATION.: NET SALES ,($MILLION)
FIGURE 59.BECTON DICKINSON AND COMPANY.: NET SALES ,($MILLION)
FIGURE 60.BIOMRIEUX SA.: NET SALES ,($MILLION)
FIGURE 61.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
FIGURE 62.SIEMENS AG.: NET SALES ,($MILLION)
FIGURE 63.HOFFMANN LA ROCHE LTD.: NET SALES ,($MILLION)
FIGURE 64.SINOCARE INC..: NET SALES ,($MILLION)

 

ページTOPに戻る


 

Summary

The point-of-care (POC) tests refer to the diagnostic procedures, which are conducted outside laboratories. POC diagnostic procedures are carried out by various POC diagnostic devices, which are used to test cholesterol and glucose levels, enzyme analysis, drug abuse testing, diagnosis of infectious diseases, and pregnancy testing. In addition, cardiac markers, fecal occult blood tests, and blood gases tests can also be performed using POC diagnostic devices.
An increase in the prevalence of various infectious diseases and several initiatives implemented by government and non-government associations for rising health awareness are major factors that drive the global point-of-care diagnostic market. In addition, technological advancements in POC diagnostic devices and introduction of home-based POC devices; and an increase in healthcare spending support the growth of the market. However, stringent government regulations for the approval of POC diagnostic devices and reimbursement issues for the POC devices are some of the major restraints that obstruct the growth of the market. Furthermore, developing countries, such as China and India provide huge growth opportunities to the global point-of-care diagnostics market.
The global point-of-care diagnostic market is segmented on the basis of product, end-user, mode of prescription, and region.
By product, the point-of-care diagnostic kit market is segmented into glucose monitoring kit, infectious diseases testing kit, pregnancy, and fertility testing kit, hematology testing kit, cardiometabolic monitoring kit, urinalysis testing kit, cholesterol test strips, drug of abuse testing kit, and others. Among these, the glucose monitoring kits segment dominates the global point-of-care diagnostics market owing to the increase in the prevalence of diabetes globally. However, the infectious disease testing kit is the fastest-growing segment during the forecast period. This is due to the rise in awareness about the various infectious diseases, rapid product launches, and initiatives implemented by government organizations for free check-ups in public places.
By end-user, the global point-of-care diagnostics market is segmented into professional diagnostic centers, research laboratories, homes, and others, Among these end users, the professional diagnostic centers dominate the global point-of-care diagnostics market.
By mode of prescription, the global point-of-care diagnostics market is segmented into prescription-based point-of-care diagnostics and over-the-counter (OTC)-based point-of-care diagnostics market. The prescription-based point-of-care diagnostics are most frequently used in healthcare facilities and prescribed by healthcare professionals.
Geographically, the market is segmented across four major regions, such as North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the point-of-care diagnostic market. Asia-Pacific region is expected to emerge as the region with maximum growth potential due to the growth in the focus of key players in emerging economies and improvement in healthcare infrastructure in the region.
The report provides extensive competitive analysis and profiles of key market players operating in the point-of-care diagnostic market, such as Abbott Laboratories, Siemens AG, Hoffmann-La Roche Ltd, SINOCARE INC., Johnson & Johnson, Sysmex Corporation, NOVA Biomedical, Danaher Corporation, Becton Dickinson, and Company, and Bio-Rad laboratories.
KEY BENEFITS FOR STAKEHOLDERS

The report provides an in-depth analysis of the global point-of-care diagnostic Kit market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Point of Care Diagnostic Kit market.



ページTOPに戻る


Table of Contents

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Glucose Monitoring Kits
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Infectious Diseases Testing Kits
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Pregnancy And Fertility Testing Kits
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Hematology Testing Kits
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Cardiometabolic Monitoring Kits
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Urinalysis Testing Kits
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Cholesterol Test Strips
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
4.9 Drugs Abuse Testing Kits
4.9.1 Key market trends, growth factors and opportunities
4.9.2 Market size and forecast, by region
4.9.3 Market analysis by country
5.0 Others
5.0.1 Key market trends, growth factors and opportunities
5.0.2 Market size and forecast, by region
5.0.3 Market analysis by country
CHAPTER 5: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION
5.1 Overview
5.1.1 Market size and forecast
5.2 Prescription Based Devices
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Otc Based Devices
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: POINT OF CARE DIAGNOSTICS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Professional Diagnostic Centers
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Research Laboratories
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Home Care
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Others
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: POINT OF CARE DIAGNOSTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product
7.2.3 North America Market size and forecast, by Mode Of Prescription
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Product
7.2.5.1.2 Market size and forecast, by Mode Of Prescription
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Product
7.2.5.2.2 Market size and forecast, by Mode Of Prescription
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Product
7.2.5.3.2 Market size and forecast, by Mode Of Prescription
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product
7.3.3 Europe Market size and forecast, by Mode Of Prescription
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Product
7.3.5.1.2 Market size and forecast, by Mode Of Prescription
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Product
7.3.5.2.2 Market size and forecast, by Mode Of Prescription
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Product
7.3.5.3.2 Market size and forecast, by Mode Of Prescription
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Product
7.3.5.4.2 Market size and forecast, by Mode Of Prescription
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Product
7.3.5.5.2 Market size and forecast, by Mode Of Prescription
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Product
7.3.5.6.2 Market size and forecast, by Mode Of Prescription
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product
7.4.3 Asia-Pacific Market size and forecast, by Mode Of Prescription
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Product
7.4.5.1.2 Market size and forecast, by Mode Of Prescription
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Product
7.4.5.2.2 Market size and forecast, by Mode Of Prescription
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Product
7.4.5.3.2 Market size and forecast, by Mode Of Prescription
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Product
7.4.5.4.2 Market size and forecast, by Mode Of Prescription
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Product
7.4.5.5.2 Market size and forecast, by Mode Of Prescription
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest Of Asia Pacific
7.4.5.6.1 Market size and forecast, by Product
7.4.5.6.2 Market size and forecast, by Mode Of Prescription
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product
7.5.3 LAMEA Market size and forecast, by Mode Of Prescription
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Product
7.5.5.1.2 Market size and forecast, by Mode Of Prescription
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Product
7.5.5.2.2 Market size and forecast, by Mode Of Prescription
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Product
7.5.5.3.2 Market size and forecast, by Mode Of Prescription
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Product
7.5.5.4.2 Market size and forecast, by Mode Of Prescription
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Johnson and Johnson
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 sysmex corporation
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Nova Biomedical
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Danaher Corporation
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Becton Dickinson and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 bioMrieux SA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Abbott Laboratories
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Siemens AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Hoffmann La Roche Ltd
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sinocare Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR GLUCOSE MONITORING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 3. POINT OF CARE DIAGNOSTICS MARKET GLUCOSE MONITORING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR INFECTIOUS DISEASES TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 5. POINT OF CARE DIAGNOSTICS MARKET INFECTIOUS DISEASES TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR PREGNANCY AND FERTILITY TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 7. POINT OF CARE DIAGNOSTICS MARKET PREGNANCY AND FERTILITY TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR HEMATOLOGY TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 9. POINT OF CARE DIAGNOSTICS MARKET HEMATOLOGY TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR CARDIOMETABOLIC MONITORING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 11. POINT OF CARE DIAGNOSTICS MARKET CARDIOMETABOLIC MONITORING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR URINALYSIS TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 13. POINT OF CARE DIAGNOSTICS MARKET URINALYSIS TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 14. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR CHOLESTEROL TEST STRIPS, BY REGION , 2020-2030,($MILLION)
TABLE 15. POINT OF CARE DIAGNOSTICS MARKET CHOLESTEROL TEST STRIPS BY COUNTRY, 2020-2030,($MILLION)
TABLE 16. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR DRUGS ABUSE TESTING KITS, BY REGION , 2020-2030,($MILLION)
TABLE 17. POINT OF CARE DIAGNOSTICS MARKET DRUGS ABUSE TESTING KITS BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 19. POINT OF CARE DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 21. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR PRESCRIPTION BASED DEVICES, BY REGION , 2020-2030,($MILLION)
TABLE 22. POINT OF CARE DIAGNOSTICS MARKET PRESCRIPTION BASED DEVICES BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR OTC BASED DEVICES, BY REGION , 2020-2030,($MILLION)
TABLE 24. POINT OF CARE DIAGNOSTICS MARKET OTC BASED DEVICES BY COUNTRY, 2020-2030,($MILLION)
TABLE 25. GLOBAL POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 26. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR PROFESSIONAL DIAGNOSTIC CENTERS, BY REGION , 2020-2030,($MILLION)
TABLE 27. POINT OF CARE DIAGNOSTICS MARKET PROFESSIONAL DIAGNOSTIC CENTERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 28. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR RESEARCH LABORATORIES, BY REGION , 2020-2030,($MILLION)
TABLE 29. POINT OF CARE DIAGNOSTICS MARKET RESEARCH LABORATORIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 30. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR HOME CARE, BY REGION , 2020-2030,($MILLION)
TABLE 31. POINT OF CARE DIAGNOSTICS MARKET HOME CARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 32. POINT OF CARE DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 33. POINT OF CARE DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 34. POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 35. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 36. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 37. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 38. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 39. U.S. POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 40. U.S. POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 41. U.S. POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 42. CANADA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 43. CANADA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 44. CANADA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 45. MEXICO POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 46. MEXICO POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 47. MEXICO POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 48. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 49. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 50. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 51. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 52. GERMANY POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 53. GERMANY POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 54. GERMANY POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 55. FRANCE POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 56. FRANCE POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 57. FRANCE POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 58. U.K. POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 59. U.K. POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 60. U.K. POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 61. ITALY POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 62. ITALY POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 63. ITALY POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. SPAIN POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. SPAIN POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 66. SPAIN POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 67. REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 68. REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 69. REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 70. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 71. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 72. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 73. ASIA-PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 74. JAPAN POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 75. JAPAN POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 76. JAPAN POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 77. CHINA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 78. CHINA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 79. CHINA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 80. AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 81. AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 82. AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 83. INDIA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 84. INDIA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 85. INDIA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 86. SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 87. SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 88. SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 89. REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 91. REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 92. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 93. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2020-2030,($MILLION)
TABLE 94. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 95. LAMEA POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 96. BRAZIL POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 97. BRAZIL POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 98. BRAZIL POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 99. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 100. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 101. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 102. SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 103. SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 104. SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 105. REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 106. REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET BY MODE OF PRESCRIPTION 2020-2030,($MILLION)
TABLE 107. REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 108.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 109.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 110.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 111.JOHNSON AND JOHNSON: NET SALES,
TABLE 112.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 113.SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 114.SYSMEX CORPORATION: OPERATING SEGMENTS
TABLE 115.SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 116.SYSMEX CORPORATION: NET SALES,
TABLE 117.SYSMEX CORPORATION: KEY STRATERGIES
TABLE 118.NOVA BIOMEDICAL: COMPANY SNAPSHOT
TABLE 119.NOVA BIOMEDICAL: OPERATING SEGMENTS
TABLE 120.NOVA BIOMEDICAL: PRODUCT PORTFOLIO
TABLE 121.NOVA BIOMEDICAL: NET SALES,
TABLE 122.NOVA BIOMEDICAL: KEY STRATERGIES
TABLE 123.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 124.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 125.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 126.DANAHER CORPORATION: NET SALES,
TABLE 127.DANAHER CORPORATION: KEY STRATERGIES
TABLE 128.BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 129.BECTON DICKINSON AND COMPANY: OPERATING SEGMENTS
TABLE 130.BECTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 131.BECTON DICKINSON AND COMPANY: NET SALES,
TABLE 132.BECTON DICKINSON AND COMPANY: KEY STRATERGIES
TABLE 133.BIOMRIEUX SA: COMPANY SNAPSHOT
TABLE 134.BIOMRIEUX SA: OPERATING SEGMENTS
TABLE 135.BIOMRIEUX SA: PRODUCT PORTFOLIO
TABLE 136.BIOMRIEUX SA: NET SALES,
TABLE 137.BIOMRIEUX SA: KEY STRATERGIES
TABLE 138.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 139.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 140.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 141.ABBOTT LABORATORIES: NET SALES,
TABLE 142.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 143.SIEMENS AG: COMPANY SNAPSHOT
TABLE 144.SIEMENS AG: OPERATING SEGMENTS
TABLE 145.SIEMENS AG: PRODUCT PORTFOLIO
TABLE 146.SIEMENS AG: NET SALES,
TABLE 147.SIEMENS AG: KEY STRATERGIES
TABLE 148.HOFFMANN LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 149.HOFFMANN LA ROCHE LTD: OPERATING SEGMENTS
TABLE 150.HOFFMANN LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 151.HOFFMANN LA ROCHE LTD: NET SALES,
TABLE 152.HOFFMANN LA ROCHE LTD: KEY STRATERGIES
TABLE 153.SINOCARE INC.: COMPANY SNAPSHOT
TABLE 154.SINOCARE INC.: OPERATING SEGMENTS
TABLE 155.SINOCARE INC.: PRODUCT PORTFOLIO
TABLE 156.SINOCARE INC.: NET SALES,
TABLE 157.SINOCARE INC.: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2.POINT OF CARE DIAGNOSTICS MARKET,2020-2030
FIGURE 3.POINT OF CARE DIAGNOSTICS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.POINT OF CARE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.POINT OF CARE DIAGNOSTICS MARKET,BY PRODUCT,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF GLUCOSE MONITORING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASES TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PREGNANCY AND FERTILITY TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CARDIOMETABOLIC MONITORING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF URINALYSIS TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CHOLESTEROL TEST STRIPS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF DRUGS ABUSE TESTING KITS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 21.POINT OF CARE DIAGNOSTICS MARKET,BY MODE OF PRESCRIPTION,2020(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PRESCRIPTION BASED DEVICES POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTC BASED DEVICES POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 24.POINT OF CARE DIAGNOSTICS MARKET,BY END USER,2020(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PROFESSIONAL DIAGNOSTIC CENTERS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF RESEARCH LABORATORIES POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF HOME CARE POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS POINT OF CARE DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 29.POINT OF CARE DIAGNOSTICS MARKET BY REGION,2020
FIGURE 30.U.S. POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 31.CANADA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 32.MEXICO POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 33.GERMANY POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 34.FRANCE POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 35.U.K. POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 36.ITALY POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 37.SPAIN POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 38.REST OF EUROPE POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 39.JAPAN POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 40.CHINA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 41.AUSTRALIA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 42.INDIA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 43.SOUTH KOREA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 44.REST OF ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 45.BRAZIL POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 46.SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 47.SOUTH AFRICA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 48.REST OF LAMEA POINT OF CARE DIAGNOSTICS MARKET,2020-2030($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 52.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53.COMPETITIVE DASHBOARD
FIGURE 54.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 55.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
FIGURE 56.SYSMEX CORPORATION.: NET SALES ,($MILLION)
FIGURE 57.NOVA BIOMEDICAL.: NET SALES ,($MILLION)
FIGURE 58.DANAHER CORPORATION.: NET SALES ,($MILLION)
FIGURE 59.BECTON DICKINSON AND COMPANY.: NET SALES ,($MILLION)
FIGURE 60.BIOMRIEUX SA.: NET SALES ,($MILLION)
FIGURE 61.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
FIGURE 62.SIEMENS AG.: NET SALES ,($MILLION)
FIGURE 63.HOFFMANN LA ROCHE LTD.: NET SALES ,($MILLION)
FIGURE 64.SINOCARE INC..: NET SALES ,($MILLION)

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Allied Market Research 社の最新刊レポート


よくあるご質問


Allied Market Research社はどのような調査会社ですか?


アライドマーケットリサーチ(Allied Market Research)は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/10/07 10:29

149.47 円

164.37 円

198.85 円

ページTOPに戻る